NbN
The Neuroscience-based nomenclature (NbN) is an initiative aimed at
updating the classification of psychiatric medication.
The goal of the NbN is to describe psychotropics in terms of
their pharmacologic properties, rather than the current disease-based nomenclature.
NbN aims to help the clinician in informed prescribing, to
decrease confusion for the patient (no more “antipsychotics” for depression or “antidepressants”
for anxiety phenomena), to harmonize psychiatry with other fields in medicine, and to provide an
important teaching tool that presents the depth and richness of the neuroscience fabric of
psychotropics.
The Neuroscience-based Nomenclature (NbN) is led by the ECNP,
in collaboration with four major international organizations: ACNP, AsCNP, CINP, and IUPHAR
NbN
Pharmacologically driven, neuroscience-based nomenclature for
psychotropics
visit site
NbN C&A
pharmacologically driven, neuroscience-based nomenclature for
child and adolescent psychotropics
visit site
NbN P&F
Neuroscience-based nomenclature adapted for patients and
families
visit site
